Consumer Health News and Research RSS Feed - Consumer Health News and Research

EMD Serono begins MSB0010718C Phase II study in mMCC patients

EMD Serono begins MSB0010718C Phase II study in mMCC patients

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the initiation of an international Phase II study designed to assess the efficacy and safety of MSB0010718C, an investigational fully human IgG1 monoclonal antibody that binds to programmed death-ligand 1 (PD-L1). [More]
Avidus acquires Truestar Health

Avidus acquires Truestar Health

Avidus Management Group Inc. is pleased to announce that further to its news release of July 16, 2014, it has completed the acquisition of substantially all of the assets of Truestar Health Inc., a Toronto based network-marketing company (the "Acquisition"). [More]
Butterfly Health campaign provides common language education on accidental bowel leakage

Butterfly Health campaign provides common language education on accidental bowel leakage

Butterfly Health launches an accidental bowel leakage (ABL) educational initiative with NAFC called "Let's Talk about Bowel Health." The campaign is designed to increase dialogue and care for ABL – a little discussed bowel health condition. [More]

Insurers' propose 2015 rate increases for health exchange plans

News outlets report on proposed 2015 premium increases in D.C. and Colorado, looking at how these rates compare nationally and how consumers are reacting. [More]
Mersana and Merck KGaA develop next-generation antibody-drug conjugates

Mersana and Merck KGaA develop next-generation antibody-drug conjugates

Mersana Therapeutics, Inc., and the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, which operates as EMD Serono in the United States and Canada, announced today an agreement to collaboratively develop next-generation antibody-drug conjugates (ADCs). [More]
Pfizer and Cellectis enter into global strategic collaboration to develop CAR-T immunotherapies

Pfizer and Cellectis enter into global strategic collaboration to develop CAR-T immunotherapies

Pfizer Inc. and Cellectis today announced that they have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets. [More]
iGetBetter selects Validic platform to access data from broad range of biometric devices

iGetBetter selects Validic platform to access data from broad range of biometric devices

iGetBetter, Inc., a supplier of post-acute care transition solutions, and Validic, the healthcare industry's premier technology platform for accessing digital health data, announced today that iGetBetter has selected the Validic platform to access data from a broad range of available biometric devices as part of its care transition solution focused on reducing readmissions. [More]
NCCN ORP awards six grants to improve care for patients with renal or hematologic malignancies

NCCN ORP awards six grants to improve care for patients with renal or hematologic malignancies

The National Comprehensive Cancer Network Oncology Research Program, in collaboration with Pfizer Independent Grants for Learning & Change, recently awarded six independent grants to health care institutions following a joint Request for Proposals (RFP) focused on the development and adoption of evidence-based initiatives to improve patient care and outcomes in renal cell carcinoma and hematologic malignancies. [More]
UnitedHealthcare recognizes employers for improving employees' health through wellness programs

UnitedHealthcare recognizes employers for improving employees' health through wellness programs

UnitedHealthcare has announced winners of its Well Deserved Award, an annual honor given to employers who have demonstrated a strong commitment to improving their employees' health and well-being through effective worksite wellness programs. [More]
UnitedHealthcare and IRONKIDS join forces to motivate young people to lead healthy lifestyles

UnitedHealthcare and IRONKIDS join forces to motivate young people to lead healthy lifestyles

UnitedHealthcare is teaming up with IRONKIDS® for the UnitedHealthcare IRONKIDS Kansas Fun Run to inspire and motivate young people to lead active, positive and healthy lifestyles. [More]
Validic adds several new clients to expand global digital health marketplace

Validic adds several new clients to expand global digital health marketplace

Validic, the healthcare industry's premier technology platform for accessing digital health data, announced today the addition of several new clients and integration partners, as they continue to expand and grow their global digital health marketplace. [More]
Sanofi and Lilly announces agreement to pursue regulatory approval of Cialis

Sanofi and Lilly announces agreement to pursue regulatory approval of Cialis

Sanofi and Eli Lilly and Company today announced an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil). [More]
Concise analysis of consumer health market in the UK

Concise analysis of consumer health market in the UK

Reportlinker.com announces that a new market research report is available in its catalogue: Consumer Health in the United Kingdom [More]
SinoVeda announces positive clinical results for EffectiCal in post-menopausal women

SinoVeda announces positive clinical results for EffectiCal in post-menopausal women

SinoVeda Canada Inc. today announces positive clinical results for EffectiCal® from its 24-week double-blind, randomized comparative clinical trial in post-menopausal women. [More]
Managing menopausal symptoms in work life extremely difficult for working women

Managing menopausal symptoms in work life extremely difficult for working women

A new national survey released today by Working Mother Media and Pfizer on the impact of menopausal symptoms on women in the workplace finds that managing menopausal symptoms in their work life is extremely or somewhat difficult for nearly half (48 percent) of working women ages 45-65 who have experienced these symptoms in the past year. [More]
ACP, CECity and Pfizer announce new initiative designed to increase adult immunization rates

ACP, CECity and Pfizer announce new initiative designed to increase adult immunization rates

The American College of Physicians (ACP), CECity, and Pfizer Inc. (NYSE:PFE) today announced a new initiative designed to increase adult immunization rates by assisting physicians and other health care providers in strongly recommending appropriate vaccination and tracking adult immunization rates for quality measurement and improvement. [More]
Pfizer reports positive results from rLP2086 Phase 2 study for invasive meningococcal disease

Pfizer reports positive results from rLP2086 Phase 2 study for invasive meningococcal disease

Pfizer Inc. announced today the results from two Phase 2 studies of bivalent rLP2086, Pfizer's recombinant vaccine candidate, currently under development for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 to 25 year olds. [More]
YourEncore announces partnership extension with Roche to provide expert solutions

YourEncore announces partnership extension with Roche to provide expert solutions

YourEncore, a leading provider of expert solutions to the life sciences, consumer health and nutrition industries, today announced a partnership extension with Roche to provide expert solutions and services to support enhancing productivity and strengthening regulatory compliance. [More]
New data from EMD Serono's multiple sclerosis portfolio to be presented at the 66th AAN Annual Meeting

New data from EMD Serono's multiple sclerosis portfolio to be presented at the 66th AAN Annual Meeting

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that new data from the company's multiple sclerosis (MS) portfolio will be presented at the American Academy of Neurology's 66th Annual Meeting, taking place from April 26 – May 3, in Philadelphia, PA. [More]
Novartis to buy Glaxosmithkline's oncology unit

Novartis to buy Glaxosmithkline's oncology unit

The deal, worth billions, will also see Novartis sell its vaccines unit to Glaxo and partner with Glaxo on their consumer divisions. Novartis also said it will sell its animal health division to Eli Lily. [More]